Recursion Pharmaceuticals Inc. has gained IND clearance from the FDA for a phase I/II trial of REC-1245 in a biomarker-enriched patient population, including patients with solid tumors and lymphoma. The trial is expected to begin in the fourth quarter of this year.
Alentis Therapeutics AG has obtained IND clearance from the FDA for ALE.P02, an anti-Claudin-1 (CLDN1) antibody-drug conjugate (ADC) with a tubulin inhibitor payload.
The gene encoding methylthioadenosine phosphorylase (MTAP) is expressed in normal tissues but 10 to 15% of tumors present deletions of MTAP expression that lead to accumulation of its metabolite 5-methylthioadenosine (MTA). Previous research has shown that selective inhibition of protein arginine methyltransferase 5 (PRMT5) in the presence of MTA may be considered a potential therapeutic strategy for the treatment of MTAP-deleted cancer.
The University of Texas System has synthesized mitogen-activated protein kinase 1 (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.
Synnovation Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Uereka Biosciences Inc. has synthesized mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer.
Spima Therapeutics SAS has announced its launch with a focus on developing innovative peptide-based immunotherapies for difficult-to-reach targets, especially protein-protein interactions.
RSS
